TD Waterhouse Canada’s Viking Therapeutics VKTX Stock Holding History

TD Waterhouse Canada’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.1K	Sell	1,550 -600	-28%	-$19.4K	﹤0.01%	1385
2026 Q1	$70.8K	Buy	2,150 +750	+54%	+$24.1K	﹤0.01%	1280
2025 Q4	$49.2K	Buy	1,400 +1,000	+250%	+$35.4K	﹤0.01%	1206
2025 Q3	$10.9K	Hold	400	–	–	﹤0.01%	1520
2025 Q2	$10.7K	Buy	400 +20	+5%	+$526	﹤0.01%	1445
2025 Q1	$9.09K	Hold	380	–	–	﹤0.01%	1425
2024 Q4	$15.3K	Hold	380	–	–	﹤0.01%	1328
2024 Q3	$23.6K	Buy	+380	New	+$22.3K	﹤0.01%	1208
2023 Q2	–	Sell	-70	Closed	-$1.23K	–	1825
2023 Q1	$1.23K	Hold	70	–	–	﹤0.01%	1575
2022 Q4	$597	Hold	70	–	–	﹤0.01%	1601
2022 Q3	$190	Hold	70	–	–	﹤0.01%	1664
2022 Q2	$197	Hold	70	–	–	﹤0.01%	1696
2022 Q1	$219	Hold	70	–	–	﹤0.01%	1738
2021 Q4	$323	Buy	+70	New	+$392	﹤0.01%	1698

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TD Waterhouse Canada's VKTX Position: Q2 2026 in Review

TD Waterhouse Canada reduced its Viking Therapeutics (VKTX) stake by 28% in Q2 2026, selling an estimated $19.4K and leaving 1,550 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

TD Waterhouse Canada first reported a position in VKTX in Q4 2021 and has held it in 14 quarters since. The position peaked at $70.8K in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

TD Waterhouse Canada held 1,550 shares of Viking Therapeutics worth $58.1K as of Q2 2026.
TD Waterhouse Canada sold 600 Viking Therapeutics shares in Q2 2026, an estimated $19.4K.
Viking Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1385 holding.
TD Waterhouse Canada first reported a position in Viking Therapeutics in Q4 2021 and has held it in 14 quarters since.
TD Waterhouse Canada's Viking Therapeutics position peaked at $70.8K in Q1 2026.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.